RU2003106391A - Новый тип кристаллов n-гидроски-2(s)-метил-5-этоксиметокси-4(s)-[n-(4-феноксифенилкарбонил)амин о] пентанамида, способ их получения и фармацевтический агент, содержащий указанное вещество в качестве активного ингредиента - Google Patents
Новый тип кристаллов n-гидроски-2(s)-метил-5-этоксиметокси-4(s)-[n-(4-феноксифенилкарбонил)амин о] пентанамида, способ их получения и фармацевтический агент, содержащий указанное вещество в качестве активного ингредиента Download PDFInfo
- Publication number
- RU2003106391A RU2003106391A RU2003106391/04A RU2003106391A RU2003106391A RU 2003106391 A RU2003106391 A RU 2003106391A RU 2003106391/04 A RU2003106391/04 A RU 2003106391/04A RU 2003106391 A RU2003106391 A RU 2003106391A RU 2003106391 A RU2003106391 A RU 2003106391A
- Authority
- RU
- Russia
- Prior art keywords
- type
- crystals
- pentanamide
- methyl
- phenoxyphenylcarbonyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/50—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (8)
1. Кристалл А типа N-гидрокси-2(S)-метил-5-этоксиметокси-4(S)-[N-(4-феноксифенилкарбонил)амино]пентанамида, характеризующийся значениями угла дифракции (20), полуширины полосы и относительной интенсивности в порошковой дифракционной рентгенограмме снятой с использованием Cu-Kα излучения, представленными в табл.1
2. Кристалл В типа N-гидрокси-2(S)-метил-5-этоксиметокси-4(S)-[N-(4-феноксифенилкарбонил)амино]пентанамида, характеризующийся значениями угла дифракции (20), полуширины полосы и относительной интенсивности в порошковой дифракционной рентгенограмме, снятой с использованием Cu-Kα излучения, представленными в табл.2
3. Способ получения кристаллов А типа по п.1, отличающийся тем, что осуществляют перекристаллизацию неочищенного N-гидрокси-2(S)-метил-5-этоксиметокси-4(S)-[N-(4-феноксифенилкарбонил)амино]пентанамида из смеси спиртового растворителя с водой.
4. Способ получения кристаллов В типа по п.1, отличающийся тем, что осуществляют перекристаллизацию неочищенного N-гидрокси-2(S)-метил-5-этоксиметокси-4(S)-[N-(4-феноксифенилкарбонил)амино]пентанамида из смеси тетрагидрофурана и циклогексана.
5. Фармацевтическая композиция, содержащая кристаллы А типа по п.1 или кристаллы В типа по п.2.
6. Твердая фармацевтическая композиция, содержащая кристаллы А типа по п.1 или кристаллы В типа по п.2.
7. Ингибитор матричной металлопротеиназы, содержащий в качестве активного ингредиента кристаллы А типа по п.1, или кристаллы В типа по п.2.
8. Фармацевтический агент для лечения и/или профилактики ревматоидного артрита, эпифазита, патологической костной резорбции, остеопороза, периодонтита, интерстициального нефрита, артериосклероза, легочной эмфиземы, цирроза печени, корнеальных нарушений, метастаза, инфильтрации и пролиферации раковых клеток, аутоиммунных заболеваний, заболеваний, вызванных сосудистой эмиграцией или инфильтрацией лейкоцитов, ангиогенеза, рассеянного склероза, аневризмы аорты, эндометриоза, остеоартрита, заболеваний, вызванных патологическим сужением сосудов, содержащий в качестве активного ингредиента кристаллы А типа по п.1, или кристаллы В типа по п.2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000-273445 | 2000-09-08 | ||
| JP2000273445 | 2000-09-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2003106391A true RU2003106391A (ru) | 2004-07-27 |
Family
ID=18759384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003106391/04A RU2003106391A (ru) | 2000-09-08 | 2001-09-07 | Новый тип кристаллов n-гидроски-2(s)-метил-5-этоксиметокси-4(s)-[n-(4-феноксифенилкарбонил)амин о] пентанамида, способ их получения и фармацевтический агент, содержащий указанное вещество в качестве активного ингредиента |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20040152785A1 (ru) |
| EP (1) | EP1316547A4 (ru) |
| KR (1) | KR20030059125A (ru) |
| CN (1) | CN1473148A (ru) |
| AU (1) | AU2001284477A1 (ru) |
| BR (1) | BR0113760A (ru) |
| CA (1) | CA2419744A1 (ru) |
| CZ (1) | CZ2003636A3 (ru) |
| HU (1) | HUP0302928A3 (ru) |
| IL (1) | IL154625A0 (ru) |
| MX (1) | MXPA03001985A (ru) |
| NO (1) | NO20031030L (ru) |
| PL (1) | PL361702A1 (ru) |
| RU (1) | RU2003106391A (ru) |
| WO (1) | WO2002020467A1 (ru) |
| ZA (1) | ZA200301869B (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0100761D0 (en) | 2001-01-11 | 2001-02-21 | Biocompatibles Ltd | Drug delivery from stents |
| RU2352558C2 (ru) * | 2003-10-21 | 2009-04-20 | Уорнер-Ламберт Компани Ллс | Полиморфная форма n-[(r)-2,3-дигидроксипропокси]-3,4-дифтор-2-(2-фтор-4 йодфениламино)бензамида |
| US7713541B1 (en) | 2006-11-21 | 2010-05-11 | Abbott Cardiovascular Systems Inc. | Zwitterionic terpolymers, method of making and use on medical devices |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6420427B1 (en) * | 1997-10-09 | 2002-07-16 | Ono Pharmaceutical Co., Ltd. | Aminobutyric acid derivatives |
-
2001
- 2001-09-07 AU AU2001284477A patent/AU2001284477A1/en not_active Abandoned
- 2001-09-07 PL PL01361702A patent/PL361702A1/xx unknown
- 2001-09-07 IL IL15462501A patent/IL154625A0/xx unknown
- 2001-09-07 CZ CZ2003636A patent/CZ2003636A3/cs unknown
- 2001-09-07 EP EP01963509A patent/EP1316547A4/en not_active Withdrawn
- 2001-09-07 MX MXPA03001985A patent/MXPA03001985A/es not_active Application Discontinuation
- 2001-09-07 KR KR10-2003-7003266A patent/KR20030059125A/ko not_active Application Discontinuation
- 2001-09-07 WO PCT/JP2001/007775 patent/WO2002020467A1/ja not_active Application Discontinuation
- 2001-09-07 CA CA002419744A patent/CA2419744A1/en not_active Abandoned
- 2001-09-07 HU HU0302928A patent/HUP0302928A3/hu unknown
- 2001-09-07 CN CNA018185525A patent/CN1473148A/zh active Pending
- 2001-09-07 BR BR0113760-3A patent/BR0113760A/pt not_active Application Discontinuation
- 2001-09-07 RU RU2003106391/04A patent/RU2003106391A/ru not_active Application Discontinuation
- 2001-09-07 US US10/362,290 patent/US20040152785A1/en not_active Abandoned
-
2003
- 2003-03-05 NO NO20031030A patent/NO20031030L/no not_active Application Discontinuation
- 2003-03-06 ZA ZA200301869A patent/ZA200301869B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002020467A1 (fr) | 2002-03-14 |
| PL361702A1 (en) | 2004-10-04 |
| CA2419744A1 (en) | 2003-02-26 |
| EP1316547A1 (en) | 2003-06-04 |
| NO20031030D0 (no) | 2003-03-05 |
| BR0113760A (pt) | 2003-07-15 |
| CZ2003636A3 (cs) | 2003-08-13 |
| HUP0302928A2 (hu) | 2003-12-29 |
| EP1316547A4 (en) | 2005-10-12 |
| KR20030059125A (ko) | 2003-07-07 |
| NO20031030L (no) | 2003-05-08 |
| US20040152785A1 (en) | 2004-08-05 |
| CN1473148A (zh) | 2004-02-04 |
| HUP0302928A3 (en) | 2005-03-29 |
| ZA200301869B (en) | 2004-06-25 |
| AU2001284477A1 (en) | 2002-03-22 |
| IL154625A0 (en) | 2003-09-17 |
| MXPA03001985A (es) | 2003-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7247746B2 (en) | Crystal forms of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine | |
| CA2305463A1 (en) | Aminobutanoic acid derivatives | |
| WO1993009090A1 (en) | Hydroxamic acid derivative | |
| JPH0770058A (ja) | α−アミノケトン誘導体 | |
| EP0434365A2 (en) | HIV protease inhibitors useful for the treatment of aids | |
| Belokon et al. | A new synthesis of enantiomerically pure syn-(S)-β-hydroxy-α-amino acids via asymmetric aldol reactions of aldehydes with a homochiral Ni (II)-glycine/(S)-BPB Schiff base complex | |
| JPH0859606A (ja) | アミノ酸から誘導される新規な光学異性体と、その製造方法と、その医薬への応用 | |
| JPS6393755A (ja) | アミド誘導体、その製法及びこの化合物を含む肥満症及び関連症治療用医薬組成物 | |
| WO2002076935A1 (fr) | Nouveau derive de l'acide lipoique et son utilisation | |
| CA2359561A1 (en) | Proteasome inhibitors | |
| Lee et al. | Synthesis and biological evaluation of chromone carboxamides as calpain inhibitors | |
| RU2003106391A (ru) | Новый тип кристаллов n-гидроски-2(s)-метил-5-этоксиметокси-4(s)-[n-(4-феноксифенилкарбонил)амин о] пентанамида, способ их получения и фармацевтический агент, содержащий указанное вещество в качестве активного ингредиента | |
| WO2000043016A1 (fr) | DERIVE DE DICARBA-closo-DODECABORANE | |
| JPH07188158A (ja) | 新規なアミノ酸誘導体と、その製造方法と、その治療への応用 | |
| EP1858913B1 (de) | Peptid-mimetika und ihre verwendung als inhibitoren des 20s proteasoms, 26s proteasoms und des immunoproteasoms | |
| Brun et al. | New Optically Active 2H‐Azirin‐3‐amines as Synthons for Enantiomerically Pure 2, 2‐Disubstituted Glycines: Synthesis of Synthons for Tyr (2Me) and Dopa (2Me), and Their Incorporation into Dipeptides | |
| JP2007506664A (ja) | マトリックスメタロプロテイナーゼの阻害剤 | |
| RU2111959C1 (ru) | N-//4,5-диокси- и 4,5,8-тригидрокси-9,10-дигидро-9,10-диоксо-2-антраценил/карбонил/аминокислоты, способ их получения и фармацевтическая композиция на их основе | |
| Detterbeck et al. | Synthesis and structure elucidation of open-chained putrescine-bisamides from Aglaia species | |
| JP2017197570A (ja) | アトルバスタチンヘミカルシウム塩の新規な結晶形、その水和物、及びその製造方法 | |
| JPH04316557A (ja) | ６−アリール環状アントラニル酸誘導体 | |
| CN109761909A (zh) | N-(4-(嘧啶-4-氨基)苯基)磺酰胺类抑制剂或其可药用的盐、其制备方法及用途 | |
| JPH05163221A (ja) | オキシ酸誘導体 | |
| CN108191733B (zh) | 一种苯-吡咯戊烷类化合物、其制备方法及抗肝纤维化用途 | |
| CN1030229A (zh) | 丁烯酸酰胺类及它们的盐类和包含它们的医药组成物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20050111 |